BI121

BI121 is a preclinical small molecule drug candidate developed by Biom Pharmaceuticals for the treatment of COVID-19 and other broad-spectrum RNA virus infections. It is a polyphenolic-rich compound isolated from the medicinal plant *Pelargonium sidoides*. BI121 functions by targeting the SARS-CoV-2 spike protein, which prevents the virus from binding to and entering host cells. Research indicates that BI121 maintains activity against multiple SARS-CoV-2 variants, suggesting potential as a broad-spectrum antiviral agent. The compound is being investigated for its ability to inhibit viral entry and replication across various RNA viruses.